The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Targeting DNA topoisomerase II in cancer chemotherapy
Open accessAbstract
Recent molecular studies have expanded the biological contexts in which topoisomerase II (TOP2) has crucial functions, including DNA replication, transcription and chromosome segregation. Although the biological functions of TOP2 are important for ensuring genomic integrity, the ability to interfere with TOP2 and generate enzyme-mediated DNA damage is an effective strategy for cancer chemotherapy. The molecular tools that have allowed an understanding of the biological functions of TOP2 are also being applied to understanding the details of drug action. These studies promise refined targeting of TOP2 as an effective anticancer strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466
Gewirtz, D. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00307-4 · Cited by 2,240
DNA TOPOISOMERASE POISONS AS ANTITUMOR DRUGS
Liu, L. F. (1989) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.58.070189.002031 · Cited by 1,811
Keeney, S., Giroux, C. N., & Kleckner, N. (1997) · Cell · doi:10.1016/s0092-8674(00)81876-0 · Cited by 1,809
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Human CtIP promotes DNA end resection
Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., Baer, R., Lukas, J., & Jackson, S. P. (2007) · Nature · doi:10.1038/nature06337 · Cited by 1,362
ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1
Zhao, H., & Piwnica-Worms, H. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.13.4129-4139.2001 · Cited by 1,091
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887
Structure and mechanism of DNA topoisomerase II
Berger, J. M., Gamblin, S. J., Harrison, S. C., & Wang, J. C. (1996) · Nature · doi:10.1038/379225a0 · Cited by 859
The mechanism of topoisomerase I poisoning by a camptothecin analog
Staker, B. L., Hjerrild, K., Feese, M. D., Behnke, C. A., Burgin, A. B., & Stewart, L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242259599 · Cited by 818
Cited by
Taxonomy, Physiology, and Natural Products of Actinobacteria
Barka, E. A., Vatsa, P., Sanchez, L., Gaveau-Vaillant, N., Jacquard, C., Klenk, H.-P., Clément, C., Ouhdouch, Y., & van Wezel, G. P. (2016) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00019-15 · Cited by 2,188
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Aging and aging-related diseases: from molecular mechanisms to interventions and treatments
Guo, J., Huang, X., Dou, L., Yan, M., Shen, T., Tang, W., & Li, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01251-0 · Cited by 1,718
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Pommier, Y., Sun, Y., Huang, S.-Y. N., & Nitiss, J. L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.111 · Cited by 950
Self-citationExploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
DNA topoisomerase II and its growing repertoire of biological functions
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2608 · Cited by 885
Self-citationType IIA topoisomerase inhibition by a new class of antibacterial agents
Bax, B. D., Chan, P. F., Eggleston, D. S., Fosberry, A., Gentry, D. R., Gorrec, F., Giordano, I., Hann, M. M., Hennessy, A., Hibbs, M., et al. (2010) · Nature · doi:10.1038/nature09197 · Cited by 860
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier, Y. (2009) · Chemical Reviews · doi:10.1021/cr900097c · Cited by 707
Doxorubicin, DNA torsion, and chromatin dynamics
Yang, F., Teves, S. S., Kemp, C. J., & Henikoff, S. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.002 · Cited by 695
Chemodynamic Therapy via Fenton and Fenton‐Like Nanomaterials: Strategies and Recent Advances
Jia, C., Guo, Y., & Wu, F. (2022) · Small · doi:10.1002/smll.202103868 · Cited by 685
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Andrew MacKay, J., Chen, M., McDaniel, J. R., Liu, W., Simnick, A. J., & Chilkoti, A. (2009) · Nature Materials · doi:10.1038/nmat2569 · Cited by 580
Yesbolatova, A., Saito, Y., Kitamoto, N., Makino-Itou, H., Ajima, R., Nakano, R., Nakaoka, H., Fukui, K., Gamo, K., Tominari, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19532-z · Cited by 533
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
Wu, C.-C., Li, T.-K., Farh, L., Lin, L.-Y., Lin, T.-S., Yu, Y.-J., Yen, T.-J., Chiang, C.-W., & Chan, N.-L. (2011) · Science · doi:10.1126/science.1204117 · Cited by 523
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Circadian Timing in Cancer Treatments
Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094626 · Cited by 476
Regulation of Single-Strand Annealing and its Role in Genome Maintenance
Bhargava, R., Onyango, D. O., & Stark, J. M. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.06.007 · Cited by 473
Human topoisomerases and their roles in genome stability and organization
Pommier, Y., Nussenzweig, A., Takeda, S., & Austin, C. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00452-3 · Cited by 464
Chemotherapy Side-Effects: Not All DNA Damage Is Equal
van den Boogaard, W. M. C., Komninos, D. S. J., & Vermeij, W. P. (2022) · Cancers · doi:10.3390/cancers14030627 · Cited by 458
Anthraquinones As Pharmacological Tools and Drugs
Malik, E. M., & Müller, C. E. (2016) · Medicinal Research Reviews · doi:10.1002/med.21391 · Cited by 448
STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
Hsu, J.-M., Xia, W., Hsu, Y.-H., Chan, L.-C., Yu, W.-H., Cha, J.-H., Chen, C.-T., Liao, H.-W., Kuo, C.-W., Khoo, K.-H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04313-6 · Cited by 434
Oxidative Cyclization in Natural Product Biosynthesis
Tang, M.-C., Zou, Y., Watanabe, K., Walsh, C. T., & Tang, Y. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00478 · Cited by 425
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 420
New insights into the activities and toxicities of the old anticancer drug doxorubicin
van der Zanden, S. Y., Qiao, X., & Neefjes, J. (2021) · The FEBS Journal · doi:10.1111/febs.15583 · Cited by 410
Imidazoles as potential anticancer agents
Ali, I., Lone, M. N., & Aboul-Enein, H. Y. (2017) · Med. Chem. Commun. · doi:10.1039/c7md00067g · Cited by 409
Dai, Y., Yang, Z., Cheng, S., Wang, Z., Zhang, R., Zhu, G., Wang, Z., Yung, B. C., Tian, R., Jacobson, O., et al. (2018) · Advanced Materials · doi:10.1002/adma.201704877 · Cited by 409
A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage
Ledesma, F. C., El Khamisy, S. F., Zuma, M. C., Osborn, K., & Caldecott, K. W. (2009) · Nature · doi:10.1038/nature08444 · Cited by 408
Quinolones: Action and Resistance Updated
Drlica, K., Hiasa, H., Kerns, R., Malik, M., Mustaev, A., & Zhao, X. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609789630947 · Cited by 376
Recent Advances in Subcellular Targeted Cancer Therapy Based on Functional Materials
Chen, W., Luo, G., & Zhang, X. (2019) · Advanced Materials · doi:10.1002/adma.201802725 · Cited by 373
New Mechanistic and Functional Insights into DNA Topoisomerases
Chen, S. H., Chan, N.-L., & Hsieh, T.-S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061809-100002 · Cited by 369
Vo, T.-T., Ryan, J., Carrasco, R., Neuberg, D., Rossi, D. J., Stone, R. M., DeAngelo, D. J., Frattini, M. G., & Letai, A. (2012) · Cell · doi:10.1016/j.cell.2012.08.038 · Cited by 348
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
Amini, L., Silbert, S. K., Maude, S. L., Nastoupil, L. J., Ramos, C. A., Brentjens, R. J., Sauter, C. S., Shah, N. N., & Abou-el-Enein, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00607-3 · Cited by 335
Anticancer cyclometalated complexes of platinum group metals and gold
Cutillas, N., Yellol, G. S., de Haro, C., Vicente, C., Rodríguez, V., & Ruiz, J. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.03.024 · Cited by 332
Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response
Beli, P., Lukashchuk, N., Wagner, S. A., Weinert, B. T., Olsen, J. V., Baskcomb, L., Mann, M., Jackson, S. P., & Choudhary, C. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.026 · Cited by 330
The design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy
Han, H.-H., Wang, H.-M., Jangili, P., Li, M., Wu, L., Zang, Y., Sedgwick, A. C., Li, J., He, X.-P., James, T. D., et al. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00673a · Cited by 299
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Baviskar, A. T., Madaan, C., Preet, R., Mohapatra, P., Jain, V., Agarwal, A., Guchhait, S. K., Kundu, C. N., Banerjee, U. C., & Bharatam, P. V. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200235u · Cited by 294
Endophytic Fungi—Alternative Sources of Cytotoxic Compounds: A Review
Uzma, F., Mohan, C. D., Hashem, A., Konappa, N. M., Rangappa, S., Kamath, P. V., Singh, B. P., Mudili, V., Gupta, V. K., Siddaiah, C. N., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00309 · Cited by 293
Norouzi, M., Yathindranath, V., Thliveris, J. A., Kopec, B. M., Siahaan, T. J., & Miller, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-68017-y · Cited by 292
The Influence of Cell Cycle Regulation on Chemotherapy
Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136923 · Cited by 290
Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy
Bailly, C. (2012) · Chemical Reviews · doi:10.1021/cr200325f · Cited by 288
Mechanisms of DNA–protein crosslink repair
Stingele, J., Bellelli, R., & Boulton, S. J. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.56 · Cited by 281
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
Marinello, J., Delcuratolo, M., & Capranico, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113480 · Cited by 258
Chen, Z., Li, H., Bian, Y., Wang, Z., Chen, G., Zhang, X., Miao, Y., Wen, D., Wang, J., Wan, G., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00910-7 · Cited by 256
Topoisomerase II beta interacts with cohesin and CTCF at topological domain borders
Uusküla-Reimand, L., Hou, H., Samavarchi-Tehrani, P., Rudan, M. V., Liang, M., Medina-Rivera, A., Mohammed, H., Schmidt, D., Schwalie, P., Young, E. J., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1043-8 · Cited by 255
Mitoxantrone, More than Just Another Topoisomerase II Poison
Evison, B. J., Sleebs, B. E., Watson, K. G., Phillips, D. R., & Cutts, S. M. (2016) · Medicinal Research Reviews · doi:10.1002/med.21364 · Cited by 253
Murai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.009 · Cited by 172
Naphthoquinones: A continuing source for discovery of therapeutic antineoplastic agents
Qiu, H., Wang, P., Lin, H., Tang, C., Zhu, H., & Yang, Y. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13141 · Cited by 118
Bossaert, M., Pipier, A., Riou, J.-F., Noirot, C., Nguyên, L.-T., Serre, R.-F., Bouchez, O., Defrancq, E., Calsou, P., Britton, S., et al. (2021) · eLife · doi:10.7554/elife.65184 · Cited by 97
“TOP2A plays key roles in DNA replication and chromosome segregation, while TOP2B is mainly associated with transcription (Pommier et al., 2016; Nitiss, 2009a; Madabhushi, 2018).”
BackgroundInfluentialThe MMS22L–TONSL heterodimer directly promotes RAD51-dependent recombination upon replication stress
Piwko, W., Mlejnkova, L. J., Mutreja, K., Ranjha, L., Stafa, D., Smirnov, A., Brodersen, M. M., Zellweger, R., Sturzenegger, A., Janscak, P., et al. (2016) · The EMBO Journal · doi:10.15252/embj.201593132 · Cited by 87
Gass, P., Lux, M. P., Rauh, C., Hein, A., Bani, M. R., Fiessler, C., Hartmann, A., Häberle, L., Pretscher, J., Erber, R., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4925-1 · Cited by 83
(2015) · Europe PMC (PubMed Central) · Cited by 39
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Mitoxantrone Inhibits HIF-1α Expression in a Topoisomerase II–Independent Pathway
Toh, Y.-M., & Li, T.-K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0235 · Cited by 32
“Mitoxantrone belongs to the clinically useful TOP2-targeting anthraquinones that are used to treat metastatic breast cancer, leukemia, and lymphoma (22, 27, 33), and it is one of the drugs approved for multiple sclerosis (34).”
BackgroundMenendez, D., Anand, J. R., Murphy, C. C., Bell, W. J., Fu, J., Slepushkina, N., Buehler, E., Martin, S. E., Lal-Nag, M., Nitiss, J. L., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28195 · Cited by 22
Self-citationA chemical screen identifies small molecules that regulate hepcidin expression
Gaun, V., Patchen, B., Volovetz, J., Zhen, A. W., Andreev, A., Pollastri, M. P., & Fraenkel, P. G. (2014) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2014.06.002 · Cited by 22
“Daunorubicin is an anti-cancer drug and DNA intercalator that inhibits Topoisomerase II resulting in breaks in double stranded DNA and increased apoptosis[56].”
BackgroundHu, X., Wu, X., Liu, H., Cheng, Z., Zhao, Z., Xiang, C., Feng, X., Takeda, S., & Qing, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27082 · Cited by 9
Metadata
- Authors
- Nitiss, J. L.
- Venue
- Nature Reviews Cancer
- Published
- 2009-04-20
- Volume
- 9
- Issue
- 5
- Pages
- 338-350
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2041051519
- Cited by
- 1,791
- References
- 128
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.